Pharmaceutical Technology on MSN
Regeneron signs $2.32BN deal with Parabilis for Helicon conjugates
Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results